恩帕格利弗洛辛显著防止QTc延长,这是由于阿米西林中毒造成的
Veysel Özgür Barış1, Esra Gedikli1, Adnan Berk Dinçsoy1
1Physiology Department, Hacettepe University, Gaziantep, Turkey.
Cardiovascular journal of Africa
|June 7, 2023
概括
恩帕格利弗洛辛显著降低了阿米西林诱导的QT和QTc间隔延长. 这一发现表明empagliflozin可能有助于预防糖尿病患者服用阿米林的心脏问题.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 恩帕格利弗洛辛 (EMPA) 是一种-葡萄糖转运体-2 抑制剂,有利于2型糖尿病的心血管结果.
- 用于各种疾病的阿米特利普提林 (AMT) 可以通过QT延长引起心脏毒性.
- 无论是EMPA还是AMT都会影响心肌细胞中的离子代谢,因此需要对它们的结合性心脏作用进行研究.
研究的目的:
- 为了评估同时使用empagliflozin和amitriptyline对QT和QTc间隔的影响.
- 为了确定empagliflozin是否可以在临床前模型中减轻阿米林诱导的QT延长.
主要方法:
- 24只雄性威斯塔尔白色老鼠被分为四组:对照组,EMPA,AMT和AMT+EMPA.
- 药物管理是通过口胃输液进行的.
- 基线时在麻醉下测量QT和QTc间隔,并在给药后1和2小时测量.
主要成果:
- 与对照组 (p ≤ 0.001) 相比,阿米林的使用显著增加了QT间隔和QTc值.
- 恩帕格利弗洛辛显著改善了阿米林诱导的QT和QTc延长.
- AMT + EMPA 组的 QT 和 QTc 间隔明显低于 AMT 组 (p < 0.01).
结论:
- 恩帕格利弗洛辛有效抵消了阿米林诱导的QT和QTc延长.
- 这种保护作用很可能归因于对抗细胞内平衡的影响.
- 进一步的临床试验可能会支持常规使用empagliflozin,以防止糖尿病患者的QT延长治疗 amitriptyline.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
219
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
219
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
52
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
52
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.5K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.5K
Antiepileptic Drugs: Glutamate Antagonists
435
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
435
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
890
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
890


